Supernus Pharmaceuticals (SUPN) Debt to Equity (2020 - 2025)
Historic Debt to Equity for Supernus Pharmaceuticals (SUPN) over the last 9 years, with Q3 2025 value amounting to $0.01.
- Supernus Pharmaceuticals' Debt to Equity fell 7685.77% to $0.01 in Q3 2025 from the same period last year, while for Sep 2025 it was $0.01, marking a year-over-year decrease of 7685.77%. This contributed to the annual value of $0.05 for FY2024, which is 1910.98% down from last year.
- Supernus Pharmaceuticals' Debt to Equity amounted to $0.01 in Q3 2025, which was down 7685.77% from $0.03 recorded in Q1 2025.
- Supernus Pharmaceuticals' Debt to Equity's 5-year high stood at $0.52 during Q4 2021, with a 5-year trough of $0.01 in Q3 2025.
- In the last 5 years, Supernus Pharmaceuticals' Debt to Equity had a median value of $0.05 in 2024 and averaged $0.12.
- Examining YoY changes over the last 5 years, Supernus Pharmaceuticals' Debt to Equity showed a top increase of 151863.38% in 2022 and a maximum decrease of 9541.53% in 2022.
- Over the past 5 years, Supernus Pharmaceuticals' Debt to Equity (Quarter) stood at $0.52 in 2021, then plummeted by 95.42% to $0.02 in 2022, then surged by 137.1% to $0.06 in 2023, then fell by 19.11% to $0.05 in 2024, then plummeted by 76.58% to $0.01 in 2025.
- Its last three reported values are $0.01 in Q3 2025, $0.03 for Q1 2025, and $0.05 during Q4 2024.